Literature DB >> 27667780

Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies.

Hong-Bae Kim1,2, Seung-Kwon Myung3,4,5, Yon Chul Park2,6, Byoungjin Park2,7.   

Abstract

Several observational epidemiological studies have reported inconsistent results on the association between the use of benzodiazepine and the risk of cancer. We investigated the association by using a meta-analysis. We searched PubMed, EMBASE, and the bibliographies of relevant articles to locate additional publications in January 2016. Three evaluators independently reviewed and selected eligible studies based on predetermined selection criteria. Of 796 articles meeting our initial criteria, a total of 22 observational epidemiological studies with 18 case-control studies and 4 cohort studies were included in the final analysis. Benzodiazepine use was significantly associated with an increased risk of cancer (odds ratio [OR] or relative risk [RR] 1.19; 95% confidence interval 1.16-1.21) in a random-effects meta-analysis of all studies. Subgroup meta-analyses by various factors such as study design, type of case-control study, study region, and methodological quality of study showed consistent findings. Also, a significant dose-response relationship was observed between the use of benzodiazepine and the risk of cancer (p for trend <0.01). The current meta-analysis of observational epidemiological studies suggests that benzodiazepine use is associated with an increased risk of cancer.
© 2016 UICC.

Entities:  

Keywords:  benzodiazepine; cancer; meta-analysis; observational study

Mesh:

Substances:

Year:  2016        PMID: 27667780     DOI: 10.1002/ijc.30443

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Statin treatment and healthy adherer effects.

Authors:  T An; J Hao; S Sun; R Li; M Yang; G Cheng; M Zou
Journal:  Osteoporos Int       Date:  2017-05-29       Impact factor: 4.507

2.  Gamma-aminobutyric Acid Type A Receptor Subunit Delta as a Potential Therapeutic Target in Gastric Cancer.

Authors:  Koichi Sawaki; Mitsuro Kanda; Hayato Baba; Yoshikuni Inokawa; Norifumi Hattori; Masamichi Hayashi; Chie Tanaka; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2022-09-20       Impact factor: 4.339

3.  Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting.

Authors:  Jaden Brandt; Wajd Alkabanni; Silvia Alessi-Severini; Christine Leong
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

Review 4.  Neurotransmitters: emerging targets in cancer.

Authors:  Shu-Heng Jiang; Li-Peng Hu; Xu Wang; Jun Li; Zhi-Gang Zhang
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

5.  Benzodiazepine Use and Long-Term Mortality in South Korean Adult Population: A Cohort Study.

Authors:  Tak Kyu Oh; Hye Youn Park; In Ae Song
Journal:  Yonsei Med J       Date:  2021-06       Impact factor: 2.759

6.  Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan.

Authors:  Ayumi Takano; Sachiko Ono; Hayato Yamana; Hiroki Matsui; Toshihiko Matsumoto; Hideo Yasunaga; Norito Kawakami
Journal:  BMJ Open       Date:  2019-07-26       Impact factor: 2.692

Review 7.  The Nervous System Contributes to the Tumorigenesis and Progression of Human Digestive Tract Cancer.

Authors:  Dayou Dai; Hao Liu
Journal:  J Immunol Res       Date:  2022-03-07       Impact factor: 4.818

Review 8.  Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research.

Authors:  Jaden Brandt; Christine Leong
Journal:  Drugs R D       Date:  2017-12

9.  Hypnotics and Risk of Cancer: A Meta-Analysis of Observational Studies.

Authors:  Tzu-Rong Peng; Li-Jou Yang; Ta-Wei Wu; You-Chen Chao
Journal:  Medicina (Kaunas)       Date:  2020-10-01       Impact factor: 2.430

Review 10.  Benzodiazepine high-doses: The need for an accurate definition.

Authors:  Jean-Marc Cloos; Christopher Y S Lim Cow; Valéry Bocquet
Journal:  Int J Methods Psychiatr Res       Date:  2021-07-31       Impact factor: 4.035

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.